![](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/6579cadd94bdad8733800a35_cognito-3dwave%201%20(3).webp)
OVERTURE was a randomized, sham-controlled, double-blind, multicenter 6-month Phase 2 trial.
![](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/6682813c622055ae6a1964ce_6579f4d95fa9ca1f03a29041_Ripple.webp)
Our Phase 2 OVERTURE trial treated both mild- and moderate Alzheimer’s participants (n=74) with a clinical presentation across the AD continuum (MMSE 14-26, inclusive). Patients were randomized 2:1 to received daily, one-hour, non-invasive gamma therapy or sham treatment. For more information on study design and end points please visit clinicaltrials.gov/study/NCT03556280.
![](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/6682800e4dfa3d309940d5df_659c5418123505819127a98d_Stocksy_txpf2f5ef135Lq300_Large_3291454.webp)
The HOPE Study is a randomized pivotal trial investigating the safety and efficacy of Cognito’s treatment in mild-to-moderate Alzheimer’s Disease.
Research Center of New Jersey
![](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/6579cadd94bdad8733800a35_cognito-3dwave%201%20(3).webp)
a Jones RW, Lebrec J,Kahle-Wrobleski K, Dell'Agnello G, Bruno G, Vellas B, Argimon JM, Dodel R, HaroJM, Wimo A, Reed C. Disease Progression in Mild Dementia due to AlzheimerDisease in an 18-Month Observational Study (GERAS): The Impact on Costs andCaregiver Outcomes. Dement Geriatr Cogn Dis Extra. 2017 Mar 20;7(1):87-100.doi: 10.1159/000461577. PMID: 28611822; PMCID: PMC5465649.
b Fox NC, Scahill RI, Crum WR,Rossor MN. Correlation between rates of brain atrophy and cognitive decline inAD. Neurology. 1999 May 12;52(8):1687-9. doi: 10.1212/wnl.52.8.1687. PMID:10331700